Alumis (ALMS) vs Collegium Pharmaceutical (COLL)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 17, 2026.
Summary
Alumis (ALMS) has outperformed Collegium Pharmaceutical (COLL) over the past year, gaining 36.3% versus a loss of 31.7%. Alumis is the larger company by market cap ($792.1 million vs $755.0 million), about 1.0 times the size. Collegium Pharmaceutical converts more of its revenue into profit, with a net margin of 8.1% versus -1011.7%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ALMS | COLL |
|---|---|---|
| Share price | $6.12 | $23.19 |
| Market cap | $792.14M | $754.96M |
| 1-day change | -3.01% | +0.04% |
| YTD return | -37.30% | -49.91% |
| 1-year return | +36.30% | -31.67% |
| 5-year return | — | +10.11% |
| P/E ratio (TTM) | — | 18.26 |
| Forward P/E | — | 3.20 |
| EPS (TTM) | $-3.86 | $1.27 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $24.05M | $780.57M |
| Revenue growth (YoY) | — | +23.62% |
| Net income (latest FY) | $-243.32M | $62.87M |
| Gross margin | — | 59.35% |
| Operating margin | -1886.92% | 23.01% |
| Net margin | -1011.75% | 8.05% |
| 52-week high | $31.35 | $50.79 |
| 52-week low | $4.37 | $21.43 |
| Distance from 52-week high | -80.48% | -54.34% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +408.66% | +111.30% |
| Average volume | 2.52M | 777.33K |
| Shares outstanding | 129.44M | 32.56M |
| Employees | 237 | 423 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ALMS has outperformed COLL by 68.0 percentage points over the past year.
- Collegium Pharmaceutical is more profitable, keeping 8.1 cents of every revenue dollar as net income versus -1011.7 cents for Alumis.
About Alumis
ALMS stock →Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. The company offers envudeucitinib, a tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis and systemic lupus erythematosus; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor that is in Phase 1 for the treatment of neuroinflammatory and neurodegenerative diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 237 employees
About Collegium Pharmaceutical
COLL stock →Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. The company's portfolio includes Jornay PM, a central nervous system stimulant prescription medicine that contains methylphenidate HCl for the treatment of attention deficit hyperactivity disorder; Belbuca, a buccal film that contains buprenorphine for severe and persistent pain that requires an extended treatment period; Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone for the management of pain severe enough to require daily; Nucynta ER and Nucynta IR, which are extended-release and immediate-release oral formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.
Health Care · Biotechnology: Pharmaceutical Preparations · 423 employees
ALMS vs COLL FAQ
Which is bigger, Alumis or Collegium Pharmaceutical?
Alumis (ALMS) is larger, with a market capitalization of $792.14M compared with $754.96M for Collegium Pharmaceutical (COLL).
Which stock has performed better over the past year, ALMS or COLL?
ALMS returned +36.30% over the past 12 months, compared with -31.67% for COLL (price return, excluding dividends). Past performance does not predict future results.
Are Alumis and Collegium Pharmaceutical in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.